AGEN Agenus Inc. - Common Stock
NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Aoû 7, 2026AGEN Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
AGEN Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
| Date ex-dividende | Division | Type |
|---|---|---|
| 12 avril 2024 | 1-for-20 | Inverse |
| 26 avril 2023 | 1019-for-1000 | Avant |
| 3 octobre 2011 | 1-for-6 | Inverse |
À propos de Agenus Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
History
Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.
In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant
In April 2014, Agenus signed a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.
Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.
In August 2023, Agenus announced a strategic restructuring to prioritize its botensilimab and balstilimab (BOT/BAL) clinical programs. The plan included a 25% reduction in its workforce (approximately 85 positions) and the temporary suspension of most preclinical and clinical programs not related to the BOT/BAL combination. The company stated the reorganization was intended to reduce annual operating expenses by approximately $40 million.
In 2025, Agenus sold their CDMO business to Zydus Lifesciences including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Zydus to commercialize their molecules in India.
Key partners and deals
In April 2014, Agenus announced a collaboration and licensing agreement with Merck. The collaboration involved the discovery and development of therapeutic antibodies to two undisclosed Merck checkpoint targets, both thought to be relevant for cancer treatment, in addition to Agenus using its proprietary Retrocyte Display® platform to discover and optimize antibodies against the targets.
In February 2014, Agenus acquired European biotechnology firm 4-Antibody, along with its Retrocyte Display technology and a portfolio of checkpoint modulator antibody candidates .
In March 2012, GlaxoSmithKline acquired two extra rights in the two firms' agreement to use Agenus' QS-21 Stimulon adjuvant. The rights give GSK the first right in negotiation of purchase of Agenus or their assets, the rights expired in 2017 after five years had lapsed.
In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences valued at up to $141 million. Under the agreement, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to a new Zydus subsidiary, Zylidac Bio LLC, for an upfront payment of $75 million. The deal also included a $16 million equity investment by Zydus in Agenus common stock and up to $50 million in potential milestone payments. Additionally, Zydus obtained exclusive rights to develop and commercialize the botensilimab and balstilimab (BOT/BAL) combination therapy in India and Sri Lanka, with Agenus eligible for a 5% royalty on net sales. The transaction was formally closed in January 2026.
Product descriptions
Checkpoint modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer cells can evolve means to evade checkpoints, and CPMs can reverse that effect, helping the immune system better fight the cancer.
Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates. The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.
The Prophage series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors. Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has established a multi-product "good manufacturing practices" facility, which has already helped process over 1,000 tumor samples from across the globe.
The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces. Agenus has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, melanoma, and malaria. In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine with QS21-Stimulon. GSK stated that the treatment was working well enough to support a regulatory filing. RTS,S is the most advanced vaccine for malaria in development.
Agenus is the sole US-manufacturer of a patented and FDA-approved triterpene glycoside extract known as (QS-21, Matrix M), which is a key component in the manufacturing of the Oxford–AstraZeneca COVID-19 as well as the Novavax COVID-19 vaccines. Supplies are tightly controlled, and the US has invoked the US Defence Production Act to preserve vaccine raw materials for its own companies.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | AGEN | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 2.8moyenne 5 ans ≈-144.8 | ≈-144.8 | · | · | |
| P/S (TTM) | 2.7 | · | 6.5 | Sous-évalué | |
| P/B (MRQ) | -1.8 | · | · | · | |
| EV / EBITDA | -16.7 | · | · | · | |
| Cours / FCF (TTM) | -3.6 | · | · | · | |
| Cours / Flux de trésorerie (TTM) | -3.6 | · | · | · | |
| EV / Revenue (VE / Chiffre d'affaires) | 3.0 | · | · | · | |
| EV / FCF (VE / FCF) | -4.4 | · | · | · | |
| Cours / Actif net tangible (MRQ) | -1.8 | · | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | AGEN | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | 27.3%moyenne 5 ans ≈-82.1% | ≈-82.1% | -156.1% | Premier rang | |
| EBITDA Margin (Marge EBITDA) | -17.7%moyenne 5 ans ≈-82.1% | ≈-82.1% | -156.1% | Premier rang | |
| Pretax Margin (Marge avant impôts) | -2.7% | · | -404.3% | Premier rang | |
| Marge nette (TTM) | 69.3%moyenne 5 ans ≈-127.4% | ≈-127.4% | -153.3% | Premier rang | |
| ROA (TTM) | 51.4%moyenne 5 ans ≈-43.8% | ≈-43.8% | -48.4% | Premier rang | |
| ROE (TTM) | -33.2%moyenne 5 ans ≈416.3% | ≈416.3% | -56.4% | Premier rang | |
| ROIC | 8.9% | · | -88.0% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | AGEN | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | -0.2moyenne 5 ans ≈-0.0 | ≈-0.0 | 0.0 | Faible endettement | |
| Ratio de liquidité (MRQ) | 0.3moyenne 5 ans ≈0.9 | ≈0.9 | 3.5 | Faible liquidité | |
| Quick Ratio (Ratio de liquidité réduite) | 0.0moyenne 5 ans ≈0.7 | ≈0.7 | 1.9 | Faible liquidité | |
| Long-Term Debt / Equity (Dette à long terme / Capitaux propres) | 0.0moyenne 5 ans ≈-0.0 | ≈-0.0 | 0.0 | Faible endettement |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | AGEN | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 10.4%moyenne 5 ans ≈40.9% | ≈40.9% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 5.2%moyenne 5 ans ≈-1.1% | ≈-1.1% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 5.3% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | AGEN | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.5moyenne 5 ans ≈0.5 | ≈0.5 | 0.3 | Premier rang | |
| Receivables Turnover (Rotation des créances) | 102.1moyenne 5 ans ≈77.6 | ≈77.6 | 7.9 | Premier rang | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$1.4M | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 10, 2026 | $-0.01 | $0.05 | -119.6% |
| 31 mars 2026 | Mai 11, 2026 | $0.00 | $2.14 | -100.0% |
| 31 décembre 2025 | $-0.31 | $-1.07 | 71.1% | |
| 30 septembre 2025 | $1.94 | $2.02 | -3.9% | |
| 30 juin 2025 | $-1.00 | $1.38 | -172.4% | |
| 31 mars 2025 | $-1.03 | $-1.69 | 39.0% | |
| 31 décembre 2024 | $-2.04 | $-2.59 | 21.3% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Cost of Revenue | $1M | $486.0K | $3M | $11M | $3M | $2M | · | · | · | · | · | $0 | |
| R&D Expense | $79M | $156M | $235M | $187M | $179M | $143M | $168M | $125M | $116M | $95M | $70M | $22M | |
| SG&A Expense | $54M | $72M | $79M | $81M | $76M | $59M | $46M | $37M | $34M | $33M | $28M | $21M | |
| Operating Income | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | $-43M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Interest Income | $345.0K | $3M | $6M | $2M | · | · | · | · | · | · | · | · | |
| Other Non-op | $72M | $6M | $37.0K | $11M | $5M | $-2M | $28.0K | $-2M | $2M | $-2M | $-6M | $2M | |
| Pretax Income | $-3M | $-232M | $-257M | · | · | · | · | · | $-121M | $-127M | $-93M | $-42M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-5M | $0 | |
| Net Income | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | · | $-121M | $-127M | $-88M | $-42M | |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| Shares (Basic) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| Shares (Diluted) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| EBITDA | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | · |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $40M | $76M | $179M | $292M | $100M | $62M | $53M | $60M | $71M | $137M | $26M | |
| Short-term Investments | · | · | · | $15M | $15M | · | · | · | · | $5M | $35M | $15M | |
| Receivables | $2M | $407.0K | $26M | $3M | $2M | $1M | $16M | $938.0K | $1M | $11M | $10M | $463.0K | |
| Inventory | · | · | · | · | · | · | $0 | $55.0K | $79.5K | $88.2K | $88.2K | $95.7K | |
| Prepaid Expense | $785.0K | $2M | $8M | $14M | $20M | $11M | $7M | $19M | $11M | $3M | $2M | $1M | |
| Other Current Assets | $1M | $2M | $2M | $3M | $3M | $2M | $1M | $1M | $1M | $838.5K | $582.3K | $640.0K | |
| Current Assets | $133M | $46M | $112M | $213M | $332M | $114M | $87M | $75M | $74M | $91M | $184M | $43M | |
| PP&E (Net) | $15M | $120M | $133M | $133M | $60M | $27M | $26M | $25M | $26M | $26M | $15M | $6M | |
| PP&E (Gross) | $63M | $193M | $195M | $187M | $111M | $74M | $69M | $63M | $60M | $57M | $45M | $34M | |
| Accum. Depreciation | $47M | $73M | $62M | $54M | $51M | $47M | $43M | $38M | $34M | $31M | $29M | $28M | |
| Goodwill | $24M | $24M | $25M | $25M | $25M | $25M | $23M | $23M | $23M | $22M | $23M | $18M | |
| Intangibles | $3M | $3M | $4M | $6M | $8M | $11M | $11M | $12M | $14M | $16M | $19M | $7M | |
| Other Non-current Assets | $3M | $6M | $9M | $4M | $10M | $4M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Accounts Payable | $83M | $61M | $61M | $41M | $30M | $17M | $14M | $14M | $8M | $5M | $4M | $2M | |
| Accrued Liabilities | $34M | $35M | $45M | $38M | $42M | $29M | $31M | $25M | $22M | $28M | $14M | $6M | |
| Current Liabilities | $323M | $221M | $256M | $189M | $157M | $130M | $122M | $68M | $56M | $41M | $29M | $9M | |
| Capital Leases | $10M | $55M | $63M | $63M | $42M | $34M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $259.0K | $738.0K | $5M | $15M | $2M | $2M | $4M | $3M | $3M | $5M | $8M | $3M | |
| Long-term Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | $6M | |
| Total Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | · | |
| Common Stock | $353.0K | $236.0K | $197.0K | $3M | $3M | $2M | $1M | $1M | $1M | $877.9K | $863.9K | $627.2K | |
| Paid-in Capital | $1.91B | $1.86B | $1.80B | $1.64B | $1.52B | $1.26B | $1.06B | $1.01B | $952M | $867M | $851M | $716M | |
| Retained Earnings | $-2.18B | $-2.18B | $-1.96B | $-1.71B | $-1.49B | $-1.47B | $-1.28B | $-1.18B | $-1.03B | $-905M | $-779M | $-691M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| AOCI | $-439.0K | $-1M | $-955.0K | $915.0K | $1M | $3M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $-271M | $-326M | $-160M | $-61M | $34M | $-204M | $-225M | $-172M | $-76M | $-39M | $71M | $23M | |
| Liabilities + Equity | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Shares Outstanding | 35,320,397 | 23,634,670 | 19,718,662 | · | · | · | · | · | · | · | · | · |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $13M | $14M | $7M | $7M | $7M | $7M | $6M | $6M | $5M | $2M | $2M | |
| Stock-based Comp | $14M | $17M | $23M | $18M | $20M | $10M | $10M | $8M | $12M | $13M | $7M | $5M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | · | $-5M | · | |
| Amort. of Intangibles | $300.0K | $500.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $462.0K | |
| Operating Cash Flow | $-77M | $-158M | $-224M | $-175M | $10M | $-139M | $-19M | $-131M | $-94M | $-80M | $-47M | $-38M | |
| CapEx | $6.0K | $576.0K | $10M | $53M | $34M | $3M | $5M | $4M | $3M | $13M | $4M | $3M | |
| Investing Cash Flow | $1M | $27.0K | $3M | $-34M | $-43M | $-4M | $-5M | $-4M | $2M | $18M | · | $-17M | |
| Debt Issued | · | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Net Debt Issued | $-2M | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Financing Cash Flow | $37M | $123M | $120M | $96M | $225M | $184M | $31M | $128M | $81M | $-2M | · | $53M | |
| Net Change in Cash | $-39M | $-36M | $-102M | $-113M | $192M | $41M | $9M | $-7M | $-11M | $-65M | $111M | $-2M | |
| Free Cash Flow | $-77M | $-159M | $-234M | $-228M | $-24M | $-143M | $-23M | $-135M | $-97M | $-92M | $-51M | · |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| Net Margin | -2.7% | -224.5% | -164.7% | -235.3% | -9.7% | · | · | · | -281.5% | -562.6% | -354.1% | · | |
| Pretax Margin | -2.7% | · | · | · | · | · | · | · | -281.5% | -562.6% | -375.8% | · | |
| EBITDA Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| ROA | -1.4% | -86.0% | -70.8% | -52.4% | -8.4% | · | · | · | -81.7% | -63.6% | -55.5% | · | |
| ROE | 1.0% | 95.5% | 232.3% | 1718.9% | 34.0% | · | · | · | 210.0% | -803.7% | -187.5% | · | |
| ROIC | 8.9% | · | · | · | · | · | · | · | -119.0% | -117.4% | -41.1% | · |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 | 0.9 | 0.7 | 1.1 | 1.3 | 2.2 | 6.4 | · | |
| Quick Ratio | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 | 0.8 | 0.6 | 0.8 | 1.1 | 2.1 | 6.3 | · | |
| Debt / Equity | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -2.2 | -3.3 | 1.6 | · | |
| LT Debt / Equity | 0.0 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -1.9 | -3.3 | 1.6 | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.9 | 0.5 | 1.0 | 0.3 | 0.3 | 0.1 | 0.2 | · | |
| Receivables Turnover | 102.1 | 7.9 | 10.9 | 46.0 | 221.1 | 10.1 | 17.4 | 35.5 | 6.9 | 2.1 | 4.8 | · |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-7.68 | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $3.84 | $4.82 | $436.77 | $347.92 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.60 | $-7.37 | $-626.46 | $-622.46 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.08 | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | $-0.81 | · | $-1.13 | $-1.13 | $-1.13 | $-1.13 |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.4% | -33.8% | 59.5% | -66.8% | 235.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | -29.5% | 21.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Net Income TTM | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | $-162M | $-121M | $-127M | $-88M | $-42M | |
| Market Cap | $111M | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $153M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | -0.3 | -1.2 | -3.0 | -574.5 | -59.4 | -98.6 | · | -56.6 | -71.6 | -78.9 | -69.0 | |
| P/S | 1.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | -0.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -7.6 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.0 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 1.3 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -386.5% | -82.8% | -33.2% | -0.17% | -1.7% | -1.0% | · | -1.8% | -1.4% | -1.3% | -1.5% |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | $34M | $30M | $26M | $24M | $27M | $25M | $24M | $28M | $84M | $24M | $25M | $23M | $28M | $23M | |
| Cost of Revenue | $0 | $0 | $0 | $642.0K | $243.0K | $137.0K | $118.0K | $146.0K | $115.0K | $107.0K | $260.0K | $303.0K | $254.0K | $2M | $8M | $308.0K | |
| R&D Expense | $15M | $12M | $8M | $24M | $27M | $22M | $34M | $41M | $37M | $44M | $67M | $51M | $59M | $57M | $53M | $46M | |
| SG&A Expense | $8M | $7M | $12M | $11M | $16M | $16M | $21M | $17M | $17M | $17M | $21M | $19M | $20M | $18M | $25M | $18M | |
| Operating Expenses | $23M | $19M | · | · | $42M | $37M | · | · | · | · | · | · | · | · | · | · | |
| Operating Income | $11M | $15M | $14M | $-5M | $-17M | $-13M | $-26M | $-32M | $-30M | $-33M | $-4M | $-46M | $-55M | $-54M | $-58M | $-42M | |
| Interest Income | $121.0K | $21.0K | $29.0K | $74.0K | $54.0K | $188.0K | $429.0K | $1M | $539.0K | $808.0K | · | · | · | · | · | · | |
| Other Non-op | $3M | $39M | $-9M | $82M | $-12.0K | $-264.0K | $-224.0K | $19.0K | $7M | $-1M | $-201.0K | $442.0K | $-244.0K | $40.0K | $980.0K | $537.0K | |
| Net Income | $-567.0K | $39M | $-11M | $64M | $-30M | $-26M | $-47M | $-67M | $-55M | $-63M | $-49M | $-65M | $-73M | $-71M | $-74M | $-57M | |
| EPS (Basic) | $-0.01 | $1.03 | $0.03 | $2.00 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| EPS (Diluted) | $-0.01 | $1.02 | $0.09 | $1.94 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| Shares (Basic) | 41,338,000 | 37,941,000 | · | 31,886,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| Shares (Diluted) | 41,338,000 | 38,285,000 | · | 32,858,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| EBITDA | $11M | $15M | · | $-5M | $-17M | $-13M | · | $-32M | $-30M | $-33M | · | $-46M | $-55M | $-54M | · | $-42M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M | $94M | $53M | $76M | $106M | $143M | $165M | $179M | $208M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | $15M | $24M | · | $10M | |
| Receivables | $15M | $7M | $2M | $538.0K | $709.0K | $354.0K | $407.0K | $207.0K | $719.0K | $476.0K | · | $1M | $1M | $1M | · | $9M | |
| Prepaid Expense | $3M | $4M | $785.0K | $885.0K | $1M | $2M | $2M | $2M | $2M | $4M | · | $16M | $9M | $11M | · | $22M | |
| Other Current Assets | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | · | $2M | $3M | $4M | · | $2M | |
| Current Assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M | $100M | $60M | · | $126M | $171M | $206M | · | $251M | |
| PP&E (Net) | $14M | $15M | $15M | $16M | $113M | $117M | $120M | $124M | $128M | $130M | · | $140M | $143M | $140M | · | $101M | |
| PP&E (Gross) | · | · | $63M | · | · | · | $193M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $48M | $48M | $47M | $47M | $75M | $76M | $73M | $71M | $68M | $65M | · | $61M | $58M | $56M | · | $53M | |
| Goodwill | $24M | $24M | $24M | $24M | $24M | $24M | $24M | $25M | $25M | $25M | · | $25M | $25M | $26M | · | $24M | |
| Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | $4M | $5M | $6M | · | $7M | |
| Other Non-current Assets | $4M | $3M | $3M | $3M | $5M | $6M | $6M | $7M | $7M | $8M | · | $11M | $9M | $4M | · | $8M | |
| Total Assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Accounts Payable | $59M | $71M | $83M | $85M | $74M | $64M | $61M | $46M | $51M | $51M | · | $41M | $52M | $47M | · | $40M | |
| Accrued Liabilities | $28M | $37M | $34M | $32M | $39M | $36M | $35M | $37M | $41M | $41M | · | $38M | $30M | $33M | · | $29M | |
| Current Liabilities | $232M | $249M | $323M | $287M | $235M | $208M | $221M | $271M | $271M | $256M | · | $198M | $204M | $191M | · | $173M | |
| Capital Leases | $10M | $10M | $10M | $10M | $53M | $54M | $55M | $55M | $56M | $62M | · | $63M | $62M | $63M | · | $64M | |
| Other Non-current Liabilities | $247.0K | $247.0K | $259.0K | $376.0K | $752.0K | $761.0K | $738.0K | $777.0K | $1M | $3M | · | $8M | $11M | $14M | · | $1M | |
| Long-term Debt | $30M | $30M | $45M | $34M | $34M | $34M | $33M | $13M | $13M | $14M | · | $13M | $13M | $14M | · | · | |
| Total Debt | $30M | $30M | · | $34M | $34M | $34M | · | $13M | $13M | $14M | · | $13M | $13M | $14M | · | $13M | |
| Common Stock | $427.0K | $385.0K | $353.0K | $329.0K | $300.0K | $266.0K | $236.0K | $217.0K | $211.0K | $210.0K | · | $4M | $4M | $3M | · | $3M | |
| Paid-in Capital | $1.95B | $1.92B | $1.91B | $1.90B | $1.88B | $1.87B | $1.86B | $1.85B | $1.83B | $1.82B | · | $1.78B | $1.75B | $1.72B | · | $1.61B | |
| Retained Earnings | $-2.14B | $-2.14B | $-2.18B | $-2.17B | $-2.24B | $-2.21B | $-2.18B | $-2.14B | $-2.07B | $-2.02B | · | $-1.91B | $-1.85B | $-1.78B | · | $-1.64B | |
| AOCI | $-450.0K | $-437.0K | $-439.0K | $-2M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | · | $-1M | $-717.0K | $917.0K | · | $644.0K | |
| Stockholders' Equity | $-199M | $-221M | $-271M | $-274M | $-355M | $-342M | $-326M | $-292M | $-241M | $-201M | · | $-129M | $-93M | $-59M | · | $-20M | |
| Liabilities + Equity | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Shares Outstanding | 42,615,618 | 38,521,761 | 35,320,397 | 32,814,429 | 30,004,430 | 26,563,545 | 23,634,670 | 21,685,192 | 21,126,226 | 20,994,143 | · | · | · | · | · | · |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $517.0K | $583.0K | $597.0K | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $4M | $1M | $3M | $3M | $4M | $3M | $5M | $5M | $4M | $4M | $5M | $6M | $6M | $5M | $4M | $4M | |
| Operating Cash Flow | $-31M | $-36M | $-17M | $-15M | $-20M | $-26M | $-29M | $-53M | $-38M | $-38M | $-40M | $-65M | $-60M | $-59M | $-47M | $-32M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $5.0K | $73.0K | $7.0K | $461.0K | $35.0K | $223.0K | $3M | $4M | $2M | $14M | $16M | |
| Investing Cash Flow | $267.0K | $69M | $780.0K | $76.0K | $281.0K | $57.0K | $-21.0K | $56.0K | $-237.0K | $229.0K | $3M | $12M | $517.0K | $-11M | $-6M | $-16M | |
| Net Debt Issued | · | $-8M | · | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $-993.0K | $15M | $7M | $11M | $4M | $24M | $5M | $79M | $15M | $7M | $18M | $38M | $56M | $24M | $28M | |
| Net Change in Cash | $-16M | $32M | $-460.0K | $-8M | $-9M | $-22M | $-4M | $-49M | $41M | $-23M | $-30M | $-36M | $-22M | $-14M | $-30M | $-20M | |
| Free Cash Flow | · | $-36M | · | · | · | $-26M | · | · | · | $-38M | · | · | · | $-60M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| Net Margin | -1.6% | 116.2% | · | 211.4% | -116.8% | -109.6% | · | -267.7% | -233.1% | -226.6% | · | -265.4% | -290.3% | -309.6% | · | -249.1% | |
| EBITDA Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| ROA | -0.32% | 20.3% | · | 27.1% | -12.6% | -11.6% | · | -23.4% | -16.2% | -19.0% | · | -16.9% | -17.5% | -16.6% | · | -13.1% | |
| ROE | 0.20% | -13.9% | · | -22.6% | 10.1% | 9.7% | · | 31.9% | 32.8% | 48.8% | · | 86.3% | 163.6% | 331.1% | · | -528.3% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | 0.4 | · | 0.5 | 0.1 | 0.1 | · | 0.2 | 0.4 | 0.2 | · | 0.6 | 0.8 | 1.1 | · | 1.5 | |
| Quick Ratio | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.1 | · | 0.2 | 0.3 | 0.2 | · | 0.5 | 0.8 | 1.0 | · | 1.3 | |
| Debt / Equity | -0.2 | -0.1 | · | -0.1 | -0.1 | -0.1 | · | -0.0 | -0.1 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.7 | |
| LT Debt / Equity | · | · | · | -0.1 | -0.1 | -0.1 | · | 0.0 | 0.0 | 0.0 | · | -0.1 | -0.1 | -0.2 | · | · |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 4.5 | 9.8 | · | 81.2 | 36.0 | 58.0 | · | 40.6 | 22.8 | 29.6 | · | 4.9 | 2.5 | 16.9 | · | 1.5 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.67 | $-5.74 | · | $-8.35 | $-11.82 | $-12.87 | · | $-13.48 | $-11.42 | $-9.59 | · | · | · | · | · | · | |
| Revenue / Share | $0.83 | $0.88 | · | $0.92 | $0.91 | $0.98 | · | $1.17 | $1.12 | $1.38 | · | $64.30 | $71.99 | $72.22 | · | $79.39 | |
| Cash Flow / Share | · | $-0.94 | · | · | · | $-1.05 | · | · | · | $-1.88 | · | · | · | $-184.56 | · | · | |
| Cash / Share | $0.44 | $0.91 | · | $0.11 | $0.32 | $0.70 | · | $2.07 | $4.44 | $2.52 | · | · | · | · | · | · | |
| EPS (TTM) | $3.04 | $2.05 | · | $-2.04 | $-7.06 | $-8.58 | · | $-10.86 | $-11.07 | $-12.48 | · | $-26.62 | $-23.52 | $-19.76 | · | $-0.84 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $133M | $124M | · | $107M | $102M | $100M | · | $160M | $160M | $161M | · | $101M | $99M | $95M | · | $90M | |
| Net Income TTM | $92M | $62M | · | $-39M | $-170M | $-195M | · | $-234M | $-231M | $-250M | · | $-283M | $-275M | $-251M | · | $-224M | |
| Market Cap | $130M | $129M | · | $126M | $137M | $40M | · | $119M | $354M | $244M | · | · | · | · | · | · | |
| Enterprise Value | $142M | $124M | · | $157M | $161M | $55M | · | $87M | $274M | $204M | · | · | · | · | · | · | |
| P/E | 1.0 | 1.6 | · | -1.9 | -0.6 | -0.2 | · | -0.5 | -1.5 | -0.9 | · | -0.8 | -1.4 | -1.5 | · | -47.9 | |
| P/S | 1.0 | 1.0 | · | 1.2 | 1.3 | 0.4 | · | 0.7 | 2.2 | 1.5 | · | · | · | · | · | · | |
| P/B | -0.7 | -0.6 | · | -0.5 | -0.4 | -0.1 | · | -0.4 | -1.5 | -1.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| EV / Revenue | 1.1 | 1.0 | · | 1.5 | 1.6 | 0.6 | · | 0.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Earnings Yield | 99.4% | 61.4% | · | -53.0% | -154.5% | -568.2% | · | -198.2% | -66.1% | -107.6% | · | -117.8% | -73.5% | -66.2% | · | -2.1% |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $114M | $103M | $156M | $98M | $296M |
| Marge d'exploitation % | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% |
| Résultat net | $-3M | $-232M | $-257M | $-231M | $-29M |
| BPA dilué | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 |
| Ratio de liquidité | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 |
| Ratio de liquidité réduite | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-77M | $-159M | $-234M | $-228M | $-24M |
Détenteurs institutionnels (13F) 116 déclarants · $53.2M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 32 (+18 vs T. préc.) | 14 (-3 vs T. préc.) | 33 (+15 vs T. préc.) | 21 (-12 vs T. préc.) | +5.0M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $8 888 511 | 2 830 736 | 16,72% | Actions |
| BlackRock, Inc. | $7 848 543 | 2 564 884 | 14,76% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $5 128 854 | 1 676 096 | 9,65% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4 368 416 | 1 427 587 | 8,22% | Actions |
| Siren, L.L.C. | $3 256 605 | 1 064 250 | 6,12% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $3 168 086 | 1 035 040 | 5,96% | Actions |
| MACKENZIE FINANCIAL CORP | $2 185 376 | 714 175 | 4,11% | Actions |
| GOLDMAN SACHS GROUP INC | $1 372 052 | 448 383 | 2,58% | Actions |
| MARSHALL WACE, LLP | $1 345 239 | 439 621 | 2,53% | Actions |
| RAYMOND JAMES FINANCIAL INC | $1 316 038 | 430 078 | 2,48% | Actions |
| GLOBEFLEX CAPITAL L P | $1 280 858 | 418 581 | 2,41% | Actions |
| STATE STREET CORP | $1 261 892 | 412 383 | 2,37% | Actions |
| Man Group plc | $1 041 701 | 340 425 | 1,96% | Actions |
| NORTHERN TRUST CORP | $961 000 | 314 052 | 1,81% | Actions |
| Connor, Clark & Lunn Investment Management Ltd. | $948 707 | 310 035 | 1,78% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $831 139 | 271 614 | 1,56% | Actions |
| MORGAN STANLEY | $801 929 | 262 068 | 1,51% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $698 739 | 228 346 | 1,31% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $549 542 | 179 589 | 1,03% | Actions |
| Susquehanna Portfolio Strategies, LLC | $485 735 | 158 737 | 0,91% | Actions |
| Cubist Systematic Strategies, LLC | $393 512 | 102 211 | 0,74% | Actions |
| Jump Financial, LLC | $318 182 | 103 981 | 0,60% | Actions |
| Bank of New York Mellon Corp | $311 424 | 101 773 | 0,59% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $304 140 | 99 392 | 0,57% | Actions |
| TWO SIGMA INVESTMENTS, LP | $301 976 | 98 685 | 0,57% | Actions |
| STRS OHIO | $235 314 | 76 900 | 0,44% | Actions |
| CANADA PENSION PLAN INVESTMENT BOARD | $205 326 | 67 100 | 0,39% | Actions |
| BANK OF AMERICA CORP /DE/ | $159 157 | 52 012 | 0,30% | Actions |
| Invesco Ltd. | $155 870 | 50 938 | 0,29% | Actions |
| WELLS FARGO & COMPANY/MN | $132 245 | 43 217 | 0,25% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $128 569 | 42 016 | 0,24% | Actions |
| Avestar Capital, LLC | $125 460 | 41 000 | 0,24% | Actions |
| DEUTSCHE BANK AG\ | $119 046 | 38 904 | 0,22% | Actions |
| TWO SIGMA ADVISERS, LP | $107 529 | 34 245 | 0,20% | Actions |
| Claro Advisors Inc. | $102 051 | 33 350 | 0,19% | Actions |
| XTX Topco Ltd | $96 849 | 31 650 | 0,18% | Actions |
| CITADEL ADVISORS LLC | $90 270 | 29 500 | 0,17% | Option d'achat |
| RHUMBLINE ADVISERS | $90 226 | 29 488 | 0,17% | Actions |
| CAPTRUST FINANCIAL ADVISORS | $88 654 | 28 972 | 0,17% | Actions |
| Engineers Gate Manager LP | $85 092 | 27 808 | 0,16% | Actions |
| CITIGROUP INC | $84 768 | 27 702 | 0,16% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $77 418 | 25 300 | 0,15% | Option d'achat |
| LPL Financial LLC | $73 948 | 24 166 | 0,14% | Actions |
| Key Client Fiduciary Advisors, LLC | $73 823 | 24 125 | 0,14% | Actions |
| OSAIC HOLDINGS, INC. | $71 786 | 23 460 | 0,14% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $67 002 | 21 896 | 0,13% | Actions |
| WOLVERINE TRADING, LLC | $63 282 | 15 900 | 0,12% | Option d'achat |
| CITADEL ADVISORS LLC | $62 730 | 20 500 | 0,12% | Option de vente |
| PRELUDE CAPITAL MANAGEMENT, LLC | $60 469 | 19 761 | 0,11% | Actions |
| PRUDENTIAL FINANCIAL INC | $59 395 | 19 410 | 0,11% | Actions |
Activistes et détenteurs de 5%+ 5 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| ZYNEXT VENTURES USA LLC, ZYNEXT VENTURES PTE LTD, ZYDUS LIFESCIENCES LTD | 23 janvier 2026 | 5,90% | Dépôt initial | · | SEC |
| Agenus Inc. (“Agenus”) ×3 dépôts | 26 mai 2023 | · | Dépôt initial | Investissement passif | SEC |
| Garo H. Armen | 22 janvier 2008 | · | Dépôt initial | Investissement passif | SEC |
| Brad M. Kelley 2) ×4 dépôts | 27 février 2003 | · | Dépôt initial | · | SEC |
| Personne déclarante non divulguée | 1 mai 2001 | · | Dépôt initial | Fusions et acquisitions / vente | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 46 initiés · 7 dirigeants · 7 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jeff D Clark | Chief Financial Officer | 18 février 2004 A | · | 0 | 0 | $0 |
| Austin Charette | Principal Accounting Officer | 24 avril 2026 A | · | 0 | 0 | $0 |
| Christine M Klaskin | PFO & PAO | 18 juin 2025 A | 23 478 | 0 | 0 | $0 |
| Evan Kearns | VP and General Counsel | 17 décembre 2020 A | · | 0 | 0 | $0 |
| Christian Cortis | Chief Strategy Officer | 23 juillet 2019 A | · | 0 | 0 | $0 |
| Alex Duncan | Chief Technology Officer | 23 juillet 2019 A | 21 026 | 0 | 0 | $0 |
| Neal Gordon | SrVP, Manufacturing Operations | 18 février 2004 A | · | 0 | 0 | $0 |
| Timothy Wright | Administrateur | 1 octobre 2026 A | 50 391 | 0 | 0 | $0 |
| Thomas L Harrison | Administrateur | 1 octobre 2026 A | 51 988 | 0 | 0 | $0 |
| Marco Tullio Marcucci | Administrateur | 5 août 2026 A | · | 0 | 0 | $0 |
| Ulf Wiinberg | Administrateur | 1 octobre 2024 A | 124 063 | 0 | 0 | $0 |
| Allison M Jeynes-Ellis | Administrateur | 5 février 2024 A | 66 176 | 0 | 0 | $0 |
| Wadih Jordan | Administrateur | 3 octobre 2022 A | · | 0 | 0 | $0 |
| Paul N Clark | Administrateur | 1 avril 2021 A | · | 0 | 0 | $0 |
| INCYTE CORP | Détenteur de 10% | 17 juin 2020 S | 16 972 968 | 0 | 0 | $0 |
| Brad M Kelley | Détenteur de 10% | 24 septembre 2003 P | 5 546 740 | 0 | 0 | $0 |
| Garo H Armen | · | 10 août 2026 A | 371 108 | 0 | 0 | $0 |
| Steven J O'Day | · | 5 août 2026 A | 57 116 | 0 | 0 | $0 |
| Susan B Hirsch | · | 5 août 2026 A | 108 725 | 0 | 0 | $0 |
| Jennifer Buell | · | 5 août 2026 A | 19 738 | 0 | 0 | $0 |
| Brian Corvese | · | 5 août 2026 A | 92 085 | 0 | 0 | $0 |
| Adam Krauss | · | 15 juin 2021 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 21 juin 2018 A | 104 270 | 0 | 0 | $0 |
| Ozer Baysal | · | 20 juin 2018 A | 58 790 | 0 | 0 | $0 |
| Karen Valentine | · | 20 juin 2018 A | 101 521 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | · | 31 mars 2017 A | · | 0 | 0 | $0 |
| Robert Benjamin Stein | · | 31 mars 2017 A | 20 986 | 0 | 0 | $0 |
| Shahzad Malik | · | 15 juin 2016 A | 1 587 302 | 0 | 0 | $0 |
| Charles Evan Ballantyne | · | 14 juin 2016 A | 24 795 | 0 | 0 | $0 |
| Tom Dechaene | · | 4 janvier 2016 A | · | 0 | 0 | $0 |
| Kerry Wentworth | · | 26 février 2014 S | 57 410 | 0 | 0 | $0 |
| John Hatsopoulos | · | 3 octobre 2011 A | 65 000 | 0 | 0 | $0 |
| ROTHWELL TIMOTHY G | · | 3 octobre 2011 J | 7 389 | 0 | 0 | $0 |
| Hyam Levitsky | · | 1 juillet 2011 A | 15 376 | 0 | 0 | $0 |
| Peter Thornton | · | 5 juin 2008 A | 5 000 | 0 | 0 | $0 |
| Eisen Margaret | · | 5 juin 2008 A | 20 000 | 0 | 0 | $0 |
| AFEYAN NOUBAR | · | 2 avril 2007 A | 0 | 0 | 0 | $0 |
| ATLEE FRANK V III | · | 2 avril 2007 A | 0 | 0 | 0 | $0 |
| Pramod Srivastava | · | 9 février 2007 S | 1 610 | 0 | 0 | $0 |
| Roman Chicz | · | 5 janvier 2007 A | · | 0 | 0 | $0 |
| Mark Kessel | · | 2 octobre 2006 A | · | 0 | 0 | $0 |
| Bruce Leicher | · | 15 septembre 2006 A | · | 0 | 0 | $0 |
| Alastair Jj Wood | · | 15 juin 2006 A | · | 0 | 0 | $0 |
| Gamil De Chadarevian | · | 28 février 2006 M | 88 610 | 0 | 0 | $0 |
| Renu Gupta | · | 24 février 2006 A | · | 0 | 0 | $0 |
| Russell Herndon | · | 8 décembre 2004 A | · | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 12 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,57% | 15 754 SH | 2 octobre 2026 | Quotidien |
| IWC · iShares Trust | 0,06% | 134 978 SH | 11 septembre 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29 536 SH | 19 août 2026 | Quotidien |
| RSSL · Global X Funds | 0,01% | 19 052 NS | 31 juillet 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1 003 811 SH | 11 septembre 2026 | Quotidien |
| IWO · iShares Trust | 0,01% | 137 756 SH | 11 septembre 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 485 158 SH | 19 août 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 159 672 SH | 19 août 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 230 345 SH | 19 août 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6 460 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5 125 SH | 19 août 2026 | Quotidien |
| IWN · iShares Trust | · | 310 686 SH | 11 septembre 2026 | Quotidien |
AGEN Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
Objectif de cours à 12 mois
3 analystes · 2026-10-04Objectif moyen $26.33 +215,0%
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.